Current Concepts in Methadone Metabolism and Transport

Area of Science:

• Pharmacology
• Genetics
• Drug Metabolism

Background:

• Methadone is crucial for opioid addiction treatment and reducing infectious disease transmission.
• Increasing use for chronic pain is linked to adverse events.
• Variability in methadone pharmacokinetics complicates treatment.

Purpose of the Study:

• To identify the key enzymes and transporters involved in methadone disposition.
• To clarify the role of CYP enzymes in methadone metabolism.
• To understand the impact of genetic variations and drug interactions on methadone pharmacokinetics.

Main Methods:

• In vitro enzymatic assays to assess methadone metabolism.
• Analysis of methadone pharmacokinetics in relation to CYP2B6 genetic polymorphisms.
• Review of existing literature on methadone drug interactions.

Main Results:

• CYP2B6, not CYP3A4, is unequivocally established as the principal enzyme metabolizing methadone in humans.
• CYP2B6 genetic variants (e.g., CYP2B6*6, CYP2B6*4) significantly influence methadone metabolism and clearance.
• Methadone disposition is susceptible to drug interactions affecting CYP2B6 activity.
• Methadone is not a substrate for major drug transporters.

Conclusions:

• CYP2B6 is the main determinant of methadone metabolism, clearance, and plasma concentrations.
• CYP2B6 genetics and drug interactions contribute significantly to interindividual variability in methadone response and safety.
• Understanding CYP2B6's role is vital for optimizing methadone therapy and minimizing adverse events.